P53 coordinates decidual sestrin 2/AMPK/mTORC1 signaling to govern parturition timing

Journal of Clinical Investigation

Volumn 126, Issue 8, 2016, Pages 2941-2954

  Deng, Wenbo ^a   Cha, Jeeyeon ^a   Yuan, Jia ^a   Haraguchi, Hirofumi ^b   Bartos, Amanda ^a   Leishman, Emma ^c   Viollet, Benoit ^d,e,f   Bradshaw, Heather B ^c   Hirota, Yasushi ^a,b   Dey, Sudhansu K ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c INDIANA UNIVERSITY   (United States)

^d INSTITUT COCHIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; NUTLIN 3; PROLACTIN; PROLACTIN RECEPTOR; PROSTAGLANDIN E; PROSTAGLANDIN E2; PROSTAGLANDIN F; PROTEIN P53; RAPAMYCIN; RESVERATROL; SESTRIN 2; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG; ANTIOXIDANT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NUCLEAR PROTEIN; SESN2 PROTEIN, HUMAN; SESTRIN 2 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRTH; CELL AGING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DECIDUA; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; INFLAMMATION; MOUSE; NONHUMAN; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; SENESCENCE; SIGNAL TRANSDUCTION; ANIMAL; BINDING SITE; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; PREGNANCY; TRANSGENIC MOUSE; UPREGULATION; UTERUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIOXIDANTS; BINDING SITES; CELL AGING; DECIDUA; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; OXIDATIVE STRESS; PARTURITION; PREGNANCY; PREMATURE BIRTH; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; UTERUS;

EID: 84987792388     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI87715     Document Type: Article

References (63)

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84.
2. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science 2014;345(6198):760-765.
3. Elovitz MA, Mrinalini C. Animal models of preterm birth. Trends Endocrinol Metab. 2004;15(10):479-487.
4. Cha J, et al. Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions. J Clin Invest. 2013;123(9):4063-4075.
5. Hirota Y, Daikoku T, Tranguch S, Xie H, Bradshaw HB, Dey SK. Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice. J Clin Invest. 2010;120(3):803-815.
6. Hirota Y, Cha J, Yoshie M, Daikoku T, Dey SK. Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice. Proc Natl Acad Sci U S A. 2011;108(44):18073-18078.
7. Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum Reprod Update. 2014;20(6):853-868.
8. Sander C, Madsen KD, Hyrup B, Nielsen HM, Rantanen J, Jacobsen J. Characterization of spray dried bioadhesive metformin microparticles for oromucosal administration. Eur J Pharm Biopharm. 2013;85(3 pt A):682-688.
9. National Institute for Health and Clinical Excellence. NICE Web site. https://www.nice.org.uk/. Accessed June 29, 2016.
10. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658-663.
11. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953-966.
12. Wheaton WW, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242.
13. Kalender A, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11(5):390-401.
14. Anisimov VN, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773.
15. Check Hayden E. Anti-ageing pill pushed as bona fide drug. Nature. 2015;522(7556):265-266.
16. Lagouge M, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109-1122.
17. Park SJ, et al. Resveratrol ameliorates agingrelated metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421-433.
18. Bitterman JL, Chung JH. Metabolic effects of resveratrol: addressing the controversies. Cell Mol Life Sci. 2015;72(8):1473-1488.
19. Budanov AV, et al. Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene. 2002;21(39):6017-6031.
20. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004;304(5670):596-600.
21. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008;134(3):451-460.
22. Poudel R, et al. Effects of resveratrol in pregnancy using murine models with reduced blood supply to the uterus. PLoS One. 2013;8(5):e64401.
23. Kim YH, Kim YS, Roh GS, Choi WS, Cho GJ. Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol. 2012;90(1):e31-e37.
24. Duca FA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med. 2015;21(5):506-511.
25. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol. 2004;6(2):168-170.
26. Foretz M, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/ AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355-2369.
27. Price NL, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675-690.
28. Gwinn DM, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214-226.
29. Ma X, et al. Decidual cell polyploidization necessitates mitochondrial activity. PLoS One. 2011;6(10):e26774.
30. Alam SM, et al. A uterine decidual cell cytokine ensures pregnancy-dependent adaptations to a physiological stressor. Development. 2007;134(2):407-415.
31. He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab. 2015;21(2):159-162.
32. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307-318.
33. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577-590.
34. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563-575.
35. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell. 2012;46(1):30-42.
36. Kenzelmann Broz D, et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev. 2013;27(9):1016-1031.
37. Sammons MA, Zhu J, Drake AM, Berger SL. TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. Genome Res. 2015;25(2):179-188.
38. Budanov AV, Lee JH, Karin M. Stressin' Sestrins take an aging fight. EMBO Mol Med. 2010;2(10):388-400.
39. Ben-Sahra I, et al. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ. 2013;20(4):611-619.
40. Jin SH, et al. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction. Toxicol Appl Pharmacol. 2013;271(1):95-105.
41. Seo K, Seo S, Han JY, Ki SH, Shin SM. Resveratrol attenuates methylglyoxal-induced mitochondrial dysfunction and apoptosis by Sestrin2 induction. Toxicol Appl Pharmacol. 2014;280(2):314-322.
42. Agarwal S, Bell CM, Taylor SM, Moran RG. p53 deletion or hotspot mutations enhance mTORC1 activity by altering lysosomal dynamics of TSC2 and Rheb. Mol Cancer Res. 2016;14(1):66-77.
43. Schroeder JK, Kessler CA, Handwerger S. Critical role for TWIST1 in the induction of human uterine decidualization. Endocrinology. 2011;152(11):4368-4376.
44. Martin-Montalvo A, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
45. Alayev A, Berger SM, Holz MK. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation. Ann N Y Acad Sci. 2015;1348(1):116-123.
46. Parmigiani A, et al. Sestrins inhibit mTORC1 kinase activation through the GATOR complex. Cell Rep. 2014;9(4):1281-1291.
47. Tomic T, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2:e199.
48. Lehraiki A, et al. Inhibition of melanogenesis by the antidiabetic metformin. J Invest Dermatol. 2014;134(10):2589-2597.
49. Lee JH, et al. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 2010;327(5970):1223-1228.
50. Lee JH, et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab. 2012;16(3):311-321.
51. Wolfson RL, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 2016;351(6268):43-48.
52. Peng M, Yin N, Li MO. Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling. Cell. 2014;159(1):122-133.
53. Chantranupong L, et al. The Sestrins interact with GATOR2 to negatively regulate the aminoacid-sensing pathway upstream of mTORC1. Cell Rep. 2014;9(1):1-8.
54. Legro RS, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551-566.
55. Cai H, et al. Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med. 2015;7(298):298ra117.
56. Baur JA, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-342.
57. Cantó C, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010;11(3):213-219.
58. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007;104(17):7217-7222.
59. Park CE, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med. 2007;39(2):222-229.
60. Um JH, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59(3):554-563.
61. Pearson KJ, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8(2):157-168.
62. Straley ME, Togher KL, Nolan AM, Kenny LC, O'Keeffe GW. LPS alters placental inflammatory and endocrine mediators and inhibits fetal neurite growth in affected offspring during late gestation. Placenta. 2014;35(8):533-538.
63. Elovitz MA, Brown AG, Breen K, Anton L, Maubert M, Burd I. Intrauterine inflammation, insufficient to induce parturition, still evokes fetal and neonatal brain injury. Int J Dev Neurosci. 2011;29(6):663-671.